Monopar Therapeutics 4

Raymond Anderson sold a total of 3,142 shares of Monopar Therapeutics common stock on 2026-08-25 in three open-market transactions under a Rule 10b5-1 plan.

On August 25, 2026, reporting person Raymond Anderson executed three open-market sales of Monopar Therapeutics common stock under a pre-arranged Rule 10b5-1 trading plan, totaling 3,142 shares at weighted-average prices between approximately $110.04 and $113.05 per share, for aggregate proceeds of roughly $350,000. The transactions were effected in multiple trades within specified price ranges (from $109.51 up to $113.11), and following these sales Anderson’s direct ownership decreased in steps from 26,169 to 25,523 and then to 23,751 shares of common stock.

Filing Facts

CIK

1645469

Ticker

MNPR

Form

4

Source Type

fda

Accession

0001437749-26-029115

Alert Tier

6